Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response질병 중증도, 면역 기억 및 이종 반응과 관련된 SARS-CoV-2 특이적 T 세포 반응의 품질 해독Article Published on 2022-04-012022-09-11 Journal: Clinical and Translational Medicine [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] absence acute infection addition anti-S IgG anti-S IgG level anti-S IgG levels antibody antibody levels approach Combination combinations comprehensive analysis coronavirus Coronaviruses correlated COVID-19 disease disease severity Endemic Endemic coronaviruses healthy donor help Heterologous hospitalised patient IFN-γ IL-2 immune memory implication Infection Mild Mild disease non-hospitalised nucleocapsid perforin polyfunctionality protective immunity robust S protein SARS-CoV-2 severe disease Specific T-cell response spike T-cell T-cell exhaustion T-cell Response Vaccine [DOI] 10.1002/ctm2.802 PMC 바로가기 [Article Type] Article
Evidence of SARS-CoV-2 symptomatic reinfection in four healthcare professionals from the same hospital despite the presence of antibodies항체가 있음에도 불구하고 같은 병원의 의료 전문가 4명에서 SARS-CoV-2 증상 재감염의 증거Article Published on 2022-04-012022-09-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Chain Reaction collected conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic disease event Evidence evidence of exposure to Follow-up Habib Bourguiba HCWs Healthcare professional healthcare worker Healthcare workers hospital IgG IgM Immune status individual Infection initial isolate natural infection occurred Patient patients polymerase chain reaction positive presence of antibody protective immunity public health Quantitative raising ranged Reinfection reported respiratory respiratory specimen reverse transcriptase reverse transcriptase-polymerase chain reaction RT-PCR SARS-CoV-2 SARS-CoV-2 variant serology specimen Symptom symptomatic the patient total Ig university vaccination variants Viral viral genome viral genomes Viral RNA viral RNAs viral sample viral samples viral sequence viral sequences were used whole-genome sequencing [DOI] 10.1016/j.ijid.2022.01.006 PMC 바로가기 [Article Type] Article
Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients면역 저하된 신장 동종이식 환자에서 SARS CoV-2 백신(BNT162b2)에 대한 체액 및 세포 면역 반응 평가Article Published on 2022-04-012022-09-11 Journal: Transplant infectious disease : an official journa [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] absence Allograft Assessing assessment belatacept BNT162b2 booster vaccinations both groups CD4+ CD8+ T-cell Cellular immune response controls Critical cytomegalovirus deficiencies demonstrated dose Efficacy examined healthy controls humoral IgG IgG response IgG responses immune immune response immune responses Immunocompromised immunosuppressive in both group individual Infection ISP kidney kidney transplant limit memory MMF mycophenolate mycophenolate mofetil no differences of BNT162b2 partial immunity Patient patients peptide peptides Pfizer Prednisone preventing infection protective immunity protocol recipient renal response responses SARS CoV-2 SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines severe deficiency severity shown spike spike IgG T-cell T-cell immunity T-cell Response T-cell responses tacrolimus vaccination Vaccine [DOI] 10.1111/tid.13813 PMC 바로가기 [Article Type] Article
Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose두 번째 백신 접종 후 180일 동안 의료 종사자(HW)에서 BNT162b 백신 2회 접종 후 세포 및 체액 면역 반응 및 돌발 감염Article Published on 2022-03-312022-09-12 Journal: Frontiers in Public Health [Category] MERS, SARS, 진단, [키워드] age all subject binding antibody BNT162b Breakthrough infection Cytopathic effect Day Delta VOC Dilution domain enrolled evaluated groups healthcare Healthcare workers highest Hospitalization human serum humoral Humoral response identify IFN-γ IgG IgG level IgG levels IgG titer Immunity individuals Infection information Live virus long-lasting maintain microneutralization mRNA vaccine mRNA vaccines neutralized neutralizing antibody Neutralizing antibody titer neutralizing responses Neutralizing titer Older Predictive protective immunity Protein remained response SARS-CoV-2 second secretion shown stages subject subjects T-cell Response tested threshold Vaccine virus Volume was determined worker Wuhan strain [DOI] 10.3389/fpubh.2022.847384 PMC 바로가기 [Article Type] Article
Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth ReviewReview Published on 2022-03-242023-06-15 Journal: Frontiers in Immunology [Category] MERS, SARS, [키워드] coronavirus Immunopathogenesis pathophysiology protective immunity Vaccine [DOI] 10.3389/fimmu.2022.835104 PMC 바로가기 [Article Type] Review
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab인플릭시맙과 베돌리주맙으로 치료받은 염증성 장질환 환자에서 SARS-CoV-2 백신 2회 투여 후 항체 붕괴, T 세포 면역 및 돌발성 감염Article Published on 2022-03-162022-09-11 Journal: Nature Communications [Category] MERS, SARS, 유전자 메커니즘, 진단, [키워드] anti-S anti-TNF antibody antibody concentration BNT162b2 Breakthrough infection breakthrough infections ChAdOx1 ChAdOx1 nCoV-19 Concentration dose drug geometric mean half-live immune responses Immunity impair induce Inflammatory bowel disease infliximab Influenza influenza vaccination integrin nCoV Necrosis of BNT162b2 p value Patient patients patients treated pneumococcal predicted protective immunity RBD required respiratory respiratory infection risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccine sustained T cell T cell response treated treatment groups tumour necrosis factor U/mL vaccination vaccination schedule vaccine doses vaccine-induced immune response vedolizumab [DOI] 10.1038/s41467-022-28517-z PMC 바로가기 [Article Type] Article
Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection증상이 있는 SARS-CoV-2 알파 감염이 있는 백신 접종 환자의 적응 면역 반응Article Published on 2022-03-082022-09-11 Journal: JCI Insight [Category] MERS, SARS, 변종, 진단, [키워드] Adaptive immunity Alpha Alpha variant antibody antibody levels Antibody titers Breakthrough infection breakthrough infections caused Cellular immune response cellular immune responses characterized Cohort COVID-19 declined defined disease ELISA Genetic variation HCs healthy control IFN-γ IgG antibody IgG antibody titers IgG titer IgG titers immune immune response immune responses infected patient infected patients Infection Infectious disease mRNA vaccination neutralization activity Neutralizing neutralizing antibody Patient protective immunity response SARS-CoV-2 SARS-CoV-2 vaccination severe disease sustained symptomatic symptomatic infection symptomatic infections symptomatic patient Symptomatic patients T cell T cell response T cell responses the SARS-CoV-2 the vaccine vaccination Viral viral variant Viral variants virus Virus neutralization virus-specific T cell [DOI] 10.1172/jci.insight.155944 PMC 바로가기 [Article Type] Article
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants백신 접종-감염 간격은 다른 변이체에 의한 돌발성 감염 후 SARS-CoV-2 Omicron에 대한 교차 중화 효능을 결정합니다.Clinical and Translational Report Published on 2022-03-042022-09-14 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Abstract acute respiratory syndrome AMED ancestors antibodies antibody approach blood sample BNT162b2 mRNA vaccine breadth Breakthrough infection breakthrough infections collected Combination complex complicate Context coronavirus correlated COVID-19 COVID-19 vaccine cross-neutralization Delta demonstrated determine development finding funding heterogeneity immune immune evasion Immune profile Immunity individual Infection Japan magnitude mRNA mRNA vaccine much higher neutralization Neutralizing activity neutralizing antibody omicron Omicron variant other variant overcome population immunity protective immunity resistance to infection robust SARS-CoV-2 sera several variants Significance significantly spike mutations suffered supported susceptibility time interval vaccinated individual vaccination Vaccine vaccinee variant variants [DOI] 10.1016/j.medj.2022.02.006 PMC 바로가기 [Article Type] Clinical and Translational Report
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2차세대 COVID-19 백신의 호흡기 점막 전달은 SARS-CoV-2의 조상 및 변이 균주 모두에 대해 강력한 보호를 제공합니다Article Published on 2022-03-032022-09-11 Journal: Cell [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] adenoviral vector adenoviral vectors Administered animal models antibody Antigen B.1.1.7 B.1.351 chimpanzee adenoviral vector COVID-19 COVID-19 vaccine develop effective Effectiveness evaluated expressing human adenoviral vector humoral Humoral immunity Immunity immunization induce Innate immunity intramuscular intramuscular immunization intramuscularly intranasal Local long-lasting memory T cell memory T cells mucosal multi-valent vaccine multivalent vaccine murine models next-generation vaccines nucleocapsid protective immunity provide RdRP respiratory respiratory mucosal immunity respiratory mucosal immunization responses robust SARS-CoV-2 SARS-CoV-2 variant Single-dose Spike protein strain T cell T cell immunity T cells the spike protein trained innate immunity trivalent Vaccine variant variants variants of concern VoC VOCs [DOI] 10.1016/j.cell.2022.02.005 PMC 바로가기 [Article Type] Article
Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patients면역 억제 환자에서 SARS-CoV-2 백신 접종에 대한 세포 및 체액 반응Article Published on 2022-03-012022-09-11 Journal: Cellular immunology [Category] SARS, 치료기술, [키워드] Activation anti-spike antibodies B-cell BNT162b2 BNT162b2 mRNA CD8 ChAdOx1 ChAdOx1 nCoV-19 cohorts comparable COVID-19 cytokine Cytokines demonstrated depleting detectable difference Efficacy elicited haematological malignancies haematological malignancy healthy healthy volunteers highest Humoral response humoral responses immunodominance immunogenic immunological responses Immunophenotyping Immunosuppressed immunosuppressed patient immunosuppressed patients Immunosuppression immunosuppressive immunosuppressive therapy less Longevity Lower memory naïve no significant differences non-responder participant Participants Patient patients treated phenotype preserved protective immunity receiving renal responders response SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines seroconvert serological seropositive Seropositivity significant difference T-cell T-cell ELISpot T-cell Response T-cell responses Th1 cytokine therapy Transplant Vaccinations vaccine immunogenicity vaccine response vaccine responses were used [DOI] 10.1016/j.cellimm.2022.104501 PMC 바로가기 [Article Type] Article